Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Método para el tratamiento de la leucemia

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOCZ20150623002
Publicado:
18/08/2015
Caducidad:
17/08/2016
Resumen:
Una institución académica checa ha desarrollado un método de tratamiento de la leucemia. Los compuestos patentados tienen la capacidad de inhibir específicamente el ciclo de las células cancerígenas, de manera que la sustancia activa puede administrarse en cantidades más pequeñas y reducir así los efectos secundarios. La innovación consiste en la inhibición de proteínas quinasas y es más selectiva. Los modelos in vivo presentan mucha menos toxicidad en tejidos normales. Se buscan socios con el fin de continuar los estudios de la fase preclínica y clinica y establecer acuerdos de investigación.

Details

Tittle:
Method for the treatment of leukaemia - tergeted biological therapeutics
Summary:
Czech academic institution developed a method for the treatment of leukaemia. The patented compounds have ability to inhibit specifically the cell cycle of cancer cells and therefore the active substance may be administered in smaller amounts than the competition, leading to a reduction in side effects. Institution seeks for a partner who would continue the preclinical stage of testing and potentially funded clinical stage. Research cooperation agreement is offered.
Description:
Czech academic institution developed a method for the treatment of leukaemia - targeted biological therapeutics (anti-leukemics). Longest-used method of treatment is chemotherapy, which is focused on the cellular structures that are common to all cells in the body. In addition to cancer cells and also acts on cells of other tissues, leading to the occurrence of many side effects. Second generation drugs invented by researchers are trying to find such molecules and processes that are specific to tumor cells (in cells normal tissues are either not present at all or only to a small extent) and develop drugs targeting these molecules and processes. Although even medication used for targeted therapies are accompanied by many undesirable effects, the incidence and severity of these effect becomes significant lower than in chemotherapy. Our inovation is based on pan-specific inhibition of protein kinases which is much more selective than previous generation grugs and our in vivo models shows much lower toxicity for normal tissues. Our molecules are effective in nano-molar concentrations and it is possibly allowing the use of very low doses of this biological drugs in the treatment of patients. Institution seeks for a partner who would continue the preclinical stage of testing and potentially funded clinical stage. Research cooperation agreement is offered.
Advantages and Innovations:
Preliminary profiling suggested that the observed cellular selectivity of our compounds is tightly linked to specific mutations. Interestingly, these compounds also possess activity towards CDKs (Cyclin-dependent kinases) and we strongly believe that such dual specificity will be the key to truly effective AML (adult acute myeloid leukemia) therapy. Similar dual mechanisms of action have recently been described for two unrelated potent small molecule inhibitor. Our compounds display nanomolar IC50 values in MV4-11 cells, similar to sunitinib, dovitinib or TG02 .
Stage of Development:
Under development/lab tested
IPs:
Secret Know-how,Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
The patent is in PCT (The Internation Patent System) stage, the coverage of the patent can be specified.

Partner sought

Type and Role of Partner Sought:
Institution seeks for a partner who would continue the preclinical stage of testing and potentially funded clinical stage. The research cooperation agreement is offered. The technology needs to be licenced to some pharmaceutical company, with knowledge how to develop the technology and possibly to get on market. We are able to provide information´s from preclinical phase and we would like to get our molecule to market.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
Czech
English
German
Spanish

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001002 Investigaciones clínicas, ensayos
06001012 Investigaciones médicas